You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Dow
AstraZeneca
Colorcon
Harvard Business School
Johnson and Johnson

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BEMPEDOIC ACID

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Bempedoic Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02666664 Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk Recruiting Esperion Therapeutics Phase 3 2016-01-01 The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
NCT02988115 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin-Intolerant Recruiting Esperion Therapeutics Phase 3 2016-12-01 The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
NCT02991118 Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Recruiting Esperion Therapeutics Phase 3 2016-12-01 The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
NCT02993406 Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Recruiting Esperion Therapeutics Phase 3 2016-12-01 The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.
NCT03001076 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Recruiting Esperion Therapeutics Phase 3 2016-12-01 The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
NCT03051100 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C Completed Esperion Therapeutics Phase 2 2017-01-19 The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
NCT03067441 Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) Active, not recruiting Esperion Therapeutics Phase 3 2017-02-03 The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bempedoic Acid

Condition Name

Condition Name for Bempedoic Acid
Intervention Trials
Hypercholesterolemia 7
Statin Adverse Reaction 3
Atherosclerotic Cardiovascular Disease 3
Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bempedoic Acid
Intervention Trials
Hypercholesterolemia 7
Cardiovascular Diseases 5
Atherosclerosis 5
Hyperlipidemias 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bempedoic Acid

Trials by Country

Trials by Country for Bempedoic Acid
Location Trials
United States 46
Canada 4
Germany 1
United Kingdom 1
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bempedoic Acid
Location Trials
Florida 5
Kentucky 4
Virginia 4
North Carolina 4
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bempedoic Acid

Clinical Trial Phase

Clinical Trial Phase for Bempedoic Acid
Clinical Trial Phase Trials
Phase 3 7
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bempedoic Acid
Clinical Trial Phase Trials
Recruiting 8
Completed 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bempedoic Acid

Sponsor Name

Sponsor Name for Bempedoic Acid
Sponsor Trials
Esperion Therapeutics 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bempedoic Acid
Sponsor Trials
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
McKinsey
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.